Loading...
XSTO
ACTI
Market cap8mUSD
Dec 04, Last price  
0.07SEK
1D
7.97%
1Q
-60.84%
Jan 2017
-99.17%
Name

Active Biotech AB publ

Chart & Performance

D1W1MN
XSTO:ACTI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.96%
Rev. gr., 5y
-11.87%
Revenues
0k
9,152,00066,359,00012,077,00053,456,00010,772,00011,356,000234,593,000219,092,000108,145,0002,265,00016,275,00019,042,00020,246,00020,051,0008,425,0006,725,0000000
Net income
-39m
L-13.97%
-135,415,000-139,180,000-207,718,000-181,586,000-223,977,000-221,065,000-94,550,000-175,015,000-212,086,000-231,512,000-193,531,000-59,584,000-108,793,000-36,878,000-36,066,000-32,117,000-49,883,000-58,691,000-45,800,000-39,400,000
CFO
-40m
L-11.68%
-192,510,000-100,133,000-186,704,000-159,463,000-224,772,000-196,320,000-46,971,000-240,396,000-102,250,000-267,090,000-217,887,000-73,163,000-46,447,000-40,647,000-35,813,000-32,216,000-46,166,000-54,850,000-45,741,000-40,400,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
URL
https://www.activebiotech.com/
IPO date
Dec 01, 1986
Employees
8
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT